Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 9Neoplasms 6Lung Neoplasms 5Neoplasm Metastasis 4Colorectal Neoplasms 4Breast Neoplasms, Male 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Inflammatory Breast Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Solid Tumor 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms, Basal Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1

Interventions

Gemcitabine 8pembrolizumab 5Paclitaxel 4Capecitabine 4Albumin-Bound Paclitaxel 4Nivolumab 3Fluorouracil 3Cyclophosphamide 3Carboplatin 3sargramostim 2poly ICLC 2fludarabine 2Prednisone 2Oxaliplatin 2Irinotecan 2Hydroxychloroquine 2Erlotinib Hydrochloride 2Dexamethasone 2Cisplatin 2130-nm albumin-bound paclitaxel 2temsirolimus 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1rucaparib 1resiquimod 1repotrectinib 1regorafenib 1pralsetinib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma × Taxes × Clear all
NCT04983407 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Aravive, Inc.

Phase 1/2 Terminated
34 enrolled

Adenocarcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡